Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Eli Lilly partners with Nvidia to build the pharma industry’s most powerful AI supercomputer, aiming to speed up drug ...

The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.

However, new research by scientists working at the Institut Pasteur’s Microbial Paleogenomics Unit finds two previously ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

India-specific database of Coronary Artery Diseases will help identify if a person has a risk factor of developing heart ...

In a breakthrough that redefines both speed and clinical potential, a new world record for the fastest human whole genome ...

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...

US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...